By Lina carolina 
A groundbreaking pan-Canadian research initiative has unveiled a revolutionary method for rapidly identifying personalized cancer treatments for young patients, leveraging the surprising utility of chicken eggs and advanced protein analysis. This pioneering approach, spearheaded by researchers from the University of British Columbia (UBC) and the BC Children’s Hospital Research Institute (BCCHR), marks a significant advancement in the fight against pediatric cancers, particularly those that prove resistant to conventional therapies.
The Genesis of a Novel Therapeutic Strategy
The development of this innovative strategy is rooted in the collaborative spirit of PROFYLE (PRecision Oncology For Young peopLE), a cornerstone initiative within the Canadian pediatric cancer network ACCESS (Advancing Childhood Cancer Experience, Science and Survivorship). ACCESS, a vast network encompassing over 30 research and funding organizations and more than 100 investigators nationwide, is dedicated to enhancing cancer outcomes for children and young adults. The specific study, published in the esteemed journal EMBO Molecular Medicine, details the successful application of this novel technique to an unnamed young patient diagnosed with a rare and aggressive pediatric cancer that had shown little response to established treatment protocols.
At the heart of this breakthrough lies the complementary power of proteomics, the study of proteins, and a sophisticated tumor-grafting technique. While genomics has long been the bedrock of personalized medicine, providing the genetic blueprint of cancer, proteomics offers a dynamic view of the cellular machinery in action. Proteins are the workhorses of the cell, directly executing genetic instructions and mediating nearly all cellular functions. Many cancer drugs are designed to target specific protein activities, making the direct analysis of a tumor’s protein profile a critical avenue for identifying vulnerabilities.
A Race Against Time: From Genomics to Proteomics
The patient at the center of this study presented a formidable challenge. After exhausting standard chemotherapy regimens and finding the tumor resistant to a drug selected through genomic analysis, conventional genetic testing offered no clear path forward. It was at this juncture that the research team, led by co-lead authors Dr. Georgina Barnabas, a postdoctoral researcher in Dr. Philipp Lange’s lab, and Tariq Bhat, a PhD student in Dr. James Lim’s lab, decided to pivot their focus to proteomics.
"With genomics alone, we couldn’t find a clear treatment option," explained Dr. Philipp Lange, a senior investigator with the Michael Cuccione Childhood Cancer Research Program at BCCHR, and a principal figure in this research. "But by looking at the tumor’s proteins, we found a critical metabolic weakness that we could target with an already approved drug."
This shift in perspective proved pivotal. Proteomic analysis revealed that the patient’s tumor was heavily reliant on a specific enzyme, SHMT2, for its metabolic processes. This enzyme plays a crucial role in generating energy for the cancer cells. Identifying this dependence provided a clear therapeutic target that had been obscured by genetic analysis alone.
The Chicken Egg Avatar: A Miniature Clinical Trial
The challenge then became how to rapidly and effectively test potential drugs against this newly identified protein target. Traditional methods of drug testing are often time-consuming and can take months, a luxury rarely afforded to patients with aggressive, treatment-resistant cancers. To overcome this hurdle, the team employed a sophisticated technique developed within the BRAvE (Better Responses through Avatars and Evidence) initiative at BCCHR.
This method involves surgically implanting a small fragment of the patient’s tumor into a developing chicken egg. The egg, acting as an "avatar host," provides a controlled and rapidly growing environment for the tumor. Within a matter of weeks, researchers can cultivate an identical replica of the patient’s tumor outside the body. This "tumor avatar" then serves as a miniature, personalized laboratory to test the efficacy of various drugs.
"This technique speeds up the process of evaluating a treatment option in a way that simply wouldn’t be possible with traditional methods," stated Dr. James Lim, another senior investigator with the Michael Cuccione Childhood Cancer Research Program at BCCHR. "We could quickly confirm whether the drug we identified through proteomics could actually work for the patient’s tumor."
Sertraline: An Unlikely Weapon Against Cancer
Armed with the knowledge of the tumor’s reliance on SHMT2 and the ability to test drugs using the chicken egg avatar, the team identified a potential therapeutic agent: sertraline. Commonly known as an antidepressant, sertraline, when used at higher concentrations, has been shown to inhibit the activity of SHMT2. The hypothesis was that by blocking this enzyme, the drug could starve the tumor of its essential energy source, thereby halting its growth.
The research team presented their findings, including the proteomic data and the results from the chicken egg avatar experiments, to a multidisciplinary panel of experts established by PROFYLE. This expert panel, comprising oncologists, researchers, and pharmacologists, rigorously reviewed the evidence and unanimously recommended sertraline as the most promising treatment option for the patient at that critical juncture.
Promising Results, Persistent Challenges
The patient was subsequently initiated on treatment with sertraline. The results, while not a complete cure, offered a significant glimmer of hope. The patient’s tumor growth demonstrably slowed, indicating that the personalized therapeutic strategy was having a tangible impact. However, the tumor did not cease to grow entirely, underscoring the complexity of pediatric cancers and the ongoing need for further therapeutic intervention.
"While there is more work to be done, this study shows that our approach can deliver personalized treatment recommendations fast enough to actually help patients with rare and difficult-to-treat cancers," Dr. Lange emphasized. "We now hope to expand this method to other children to identify effective treatments faster across the country."
Broader Implications and Future Directions
The success of this pan-Canadian collaboration carries profound implications for the future of pediatric cancer treatment. The integration of proteomics with rapid ex vivo tumor modeling, like the chicken egg avatar system, offers a powerful paradigm shift. It moves beyond static genetic information to dynamic, functional insights into cancer biology, enabling a more nuanced and effective approach to drug selection.
The ability to quickly test drug efficacy in a personalized avatar system has the potential to significantly reduce the time between diagnosis and effective treatment, a critical factor in improving patient outcomes, especially for children facing aggressive or rare cancers. This approach also opens doors for repurposing existing drugs, such as sertraline, which can be more readily available and have established safety profiles, accelerating their application in oncology.
Furthermore, the BRAvE initiative at BCCHR, which facilitates the seamless connection between clinical care and research laboratories, provides a crucial infrastructure for translating such innovative research into tangible patient benefits. The collaborative nature of ACCESS, bringing together diverse expertise from across Canada, is instrumental in scaling these advancements to benefit children nationwide.
While the study highlights the potential of this combined approach, it also underscores the inherent challenges in treating pediatric cancers. The persistence of tumor growth even with targeted therapy suggests that more complex treatment strategies, possibly involving combinations of drugs or further refinement of the proteomic targets, may be necessary.
Looking ahead, the research team intends to expand the application of this method to a larger cohort of children with rare and refractory cancers. The goal is to further validate the efficacy and efficiency of this integrated proteomic and avatar-based approach, with the ultimate aim of establishing it as a standard of care in pediatric oncology. This innovative strategy represents a significant step forward in the quest to deliver precise, rapid, and life-saving treatments to young cancer patients, offering renewed hope and a more personalized future in the fight against childhood cancer.